Public Release: 

Society for Biomolecular Screening to hold ninth annual conference

'Drug Discovery: At The Cutting Edge' will highlight inter-disciplinary breakthroughs and key trends

Society for Biomolecular Sciences

Portland, OR: September 21 - 25, 2003

The Ninth Annual Society for Biomolecular Screening Conference, the leading industry and scientific event in drug discovery and related technologies and disciplines, will be held at the Oregon Convention Center in Portland from Sunday, September 21 through Thursday, September 25, 2003.

More than 3000 eminent scientists, innovators, and researchers -- as well as industry analysts representing a broad range of disciplines and companies from around the world -- are expected to gather to learn about the latest trends and basic and applied research that are dramatically transforming the way new pharmaceuticals are developed. These emerging developments are expected to help optimize the drug discovery process, making it faster, more efficient, and more cost-effective.

Sponsored by the Society for Biomolecular Screening (SBS), the only non-profit international scientific society dedicated to drug discovery sciences, the annual conference highlights the growing trend towards an inter-disciplinary approach to the development of pharmaceuticals. Through numerous presentations, forums, and workshops, it also promotes close-knit alliances and networking between industry and academia, as well as inter-disciplinary education among thought leaders in the molecular sciences, including biology, chemistry, bioinformatics, genomics, pharmaceutics, and biotechnology.

The five-day conference will include keynotes, feature presentations, tutorials, and workshops on emerging techniques, emphasizing the growing integration of the sciences and their effects on drug development. Breaking news and breakthrough research will be presented, as well as the latest advances in genomics, proteomics, high-throughput screening, ADMET, imaging, medicinal (all therapeutic areas), combinatorial and organic chemistry, nanotechnology, fluorescence and luminescence, micro- and nano-scale bioscience, bioinformatics, in-vitro, in-silico, and in-vivo molecular modeling, and robotics.

Some of the world's most influential scientists -- such as Dr. Leroy Hood, Dr. Roger Perlmutter, and Dr. Christopher Lipinski, among others -- will provide insights into systems biology, the executive's role in drug discovery, and controversies in the field. Corporations slated to participate include, among others, Pfizer, Merck, Glaxo SmithKline, Bristol-Myers Squibb, Amgen, Proctor & Gamble, Hoffman-La Roche, Eli Lilly, Schroedinger, Millennium Pharmaceuticals, Promega Corp., Nanostream, Pharmacia, and Genentech.

According to conference program chairs Dr. Al Kolb and Dr. John Wang, the expanding role of complementary disciplines will be a major focal point of the conference. The goal is to promote an increased level of cooperation and understanding between industry and academia, and branches of science that have previously been unconnected.

More than 400 peer-reviewed poster abstracts will also be presented, so that attendees can learn at a glance about the latest developments in different scientific disciplines.

New products and services will also be unveiled in visual presentations by such companies as Cyntellect, Hoffmann-La Roche, Cambrex, Vitra Bioscience, Genomic Solutions, Micronic Systems, NA, Euroscreen, Signature BioScience, and Graffinity Pharmaceuticals AG.

Keynote Speakers

Keynote Addresses will be presented on Monday, September 22, from 9:30 am - 11:40 am.

Dr. Roger M. Perlmutter, Executive Vice President for Research and Development for Amgen and one of the world's foremost authorities on immunology and molecular biology, will present the first keynote address: "An Executive View of Drug Discovery" Dr. Perlmutter also serves on the Board of Directors of The Institute for Systems Biology.

Other opening session speakers include Dr. Christopher A. Lipinski of Pfizer Global R&D (retired), a leading academic, researcher and holder of 17 issued US patents, who will speak on "Discipline-Based Disconnects between Medicinal Chemistry and Biology Screening." Dr. Lipinski is the originator of the "Rule of Five," a widely-used criteria filter for the screening of molecules. Dr. Lipinski recently was named a member of the Scientific Advisory Committee of the Global Alliance for TB Drug Development.

Dr. Martin Rosenberg, Vice-President of Research and Development for the Promega Corporation and former Senior Vice-President of Anti-Infectives in Drug Discovery of Glaxo SmithKline, will be speaking on "From Genomics to Medicines: Opportunities and Hurdles." He has published more than 200 papers and is a named inventor on over more than 50 issued patents. He is Editor of "Current Opinion in Biotechnology" and serves as a Member of the FDA Science Board.

SBS Awards

The Society for Biomolecular Screening will present its annual achievement awards on Wednesday, September 25 from 8:55 am - 9:55am.

Dr. Leroy Hood, one of the world's leading scientists in molecular biotechnology and genomics, and recipient of the SBS Achievement Award in 2001, will present this year's SBS Achievement Award Lecture on Wednesday, September 24. The award celebrates outstanding achievement in research and innovation. Dr. Hood is the President and Director of the Institute for Systems Biology in Seattle, which pioneers systems approaches to biology and medicine and has also played a role in several biotechnology companies including Amgen, Applied Biosystems, Systemix, Darwin and Rosetta. His inventions include the protein sequencer, the protein synthesizer, the DNA sequencer, and the DNA synthesizer. Dr. Hood was recently awarded the 2003 Lemelson-MIT Prize for Invention and Innovation.

Jonathan Ellman, Professor of Chemistry at the University of California at San Francisco in the Department of Cellular and Molecular Pharmacology, will receive the 2003 SBS Achievement Award. His laboratory is engaged in the development of chemical tools to study protein function. Dr. Ellman's 2003 SBS Achievement Award Lecture, entitled "Systems-Based Combinatorial Chemistry," will be presented on Tuesday, September 23.

The PerkinElmer Life Sciences Award for Innovation in HTS will be presented to Burleigh Hutchins. Mr. Hutchins is Director of Engineering at Sensors for Medicine and Science, and is the co-founder and former Chairman of the Board and Chief Technology Officer for Zymark Corp. He has more than two-dozen issued patents.

The SBS Accomplishment Award recipients will be Michael Knapp, co-founder of Caliper Technologies and Wallace Parce, Vice President of Research and Chief Technical Officer for Nanosys, Inc. The award recognizes significant technical accomplishment, exceeding a benchmark or milestone in screening.

The SBS PolyPops Foundation Award for Best Innovation in Microplate Design or Application will be presented to Jeff Kark, CEO and President of Boston Innovation, Inc. Dr. Kark holds 14 patents and has invented products for Proctor & Gamble, SmithKline Beecham, GlaxoWellcome and Moen, among others.

Additional awards include the SBS PolyPops Foundation Award for Best Conference Presentation and the SBS 10 Best Poster Awards.

###

About SBS

The Society for Biomolecular Screening (http://www.sbsonline.org) is the only non-profit international scientific society dedicated to drug discovery and its related disciplines. It provides a forum for global education and information exchange among inter-disciplinary professionals in the chemical, pharmaceutical, biotech and agrochemical industries.

The SBS Annual Conference and Exhibition is the premiere event in molecular discovery. The five-day event is expected to bring together more than 3000 professionals to learn about the latest breakthroughs, research, trends, technologies and equipment.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.